{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:17:03Z","timestamp":1790583423997,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Applied Radiation and Isotopes"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.apradiso.2017.04.028","type":"journal-article","created":{"date-parts":[[2017,4,23]],"date-time":"2017-04-23T02:48:46Z","timestamp":1492915726000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A systematic study on the utility of CHX-A\u2019\u2019-DTPA-NCS and NOTA-NCS as bifunctional chelators for 177 Lu radiopharmaceuticals"],"prefix":"10.1016","volume":"127","author":[{"given":"Usha","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Gamre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad Pandurang","family":"Lohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apradiso.2017.04.028_bib1","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1021\/cr500171e","article-title":"Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry and practical applications","volume":"115","author":"Banerjee","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.apradiso.2017.04.028_bib2","first-page":"882","article-title":"Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies","volume":"35","author":"Camera","year":"1994","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2017.04.028_bib3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.nucmedbio.2013.05.011","article-title":"Tracer level radiochemistry to clinical dose preparation of 177Lu-labeled cyclic RGD peptide dimer","volume":"40","author":"Chakraborty","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.apradiso.2017.04.028_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10967-014-3169-z","article-title":"On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experience","volume":"302","author":"Chakraborty","year":"2014","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"10.1016\/j.apradiso.2017.04.028_bib5","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/jlcr.3414","article-title":"Prospects of medium specific activity 177Lu in targeted therapy of prostate cancer using 177Lu-labeled PSMA inhibitor","volume":"59","author":"Chakraborty","year":"2016","journal-title":"J. Label. Comp. Radiopharm."},{"key":"10.1016\/j.apradiso.2017.04.028_bib6","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.bmc.2014.12.035","article-title":"Synthesis and comparative biological evaluation of bifunctional ligands for radiotherapy applications of 90Y and 177Lu","volume":"23","author":"Chong","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.apradiso.2017.04.028_bib7","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1039\/c0dt01599g","article-title":"Radiometallated peptides for molecular imaging and targeted therapy","volume":"40","author":"Correia","year":"2011","journal-title":"Dalton Trans."},{"key":"10.1016\/j.apradiso.2017.04.028_bib8","first-page":"1467","article-title":"Dosimetry in peptide radionuclide receptor therapy: a review","volume":"47","author":"Cremonesi","year":"2006","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2017.04.028_bib9","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1021\/cr3003104","article-title":"Radiometals for combined imaging and therapy","volume":"113","author":"Cutler","year":"2013","journal-title":"Chem. Rev."},{"key":"10.1016\/j.apradiso.2017.04.028_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.apradiso.2006.09.011","article-title":"On the preparation of a therapeutic dose of 177Lu labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor","volume":"65","author":"Das","year":"2007","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.apradiso.2017.04.028_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","article-title":"Production of 177Lu for targeted radionuclide therapy: available options","volume":"49","author":"Dash","year":"2015","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.apradiso.2017.04.028_bib12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cmmi.491","article-title":"Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators","volume":"7","author":"D'Huyvetter","year":"2012","journal-title":"Contrast Media Mol. Imaging"},{"key":"10.1016\/j.apradiso.2017.04.028_bib13","first-page":"108","article-title":"Radiolabeling and evaluation of two 177Lu labeled bis phosphonates","volume":"23","author":"Fakhari","year":"2015","journal-title":"Iran. J. Nucl. Med."},{"key":"10.1016\/j.apradiso.2017.04.028_bib14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2174\/157017911796117250","article-title":"Strategies for the preparation of bifunctional gadolinium(III) chelators","volume":"8","author":"Frullano","year":"2011","journal-title":"Curr. Org. Synth."},{"key":"10.1016\/j.apradiso.2017.04.028_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1089\/cbr.2010.0825","article-title":"Development of a 177Lu-labeled RGD derivative for targeting angiogenesis","volume":"25","author":"Hwan Ju","year":"2010","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.apradiso.2017.04.028_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1089\/cbr.2015.1836","article-title":"Evaluation of the potential of 177Lu-CHX-A'\u2019-DTPA-Rituximab as a radioimmunotherapeutic agent for Non-Hodgkin's Lymphoma","volume":"30","author":"Kameswaran","year":"2015","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.apradiso.2017.04.028_bib17","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1021\/bc200696b","article-title":"Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy","volume":"23","author":"Kang","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.apradiso.2017.04.028_bib18","doi-asserted-by":"crossref","first-page":"7080s","DOI":"10.1158\/1078-0432.CCR-1004-0019","article-title":"Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A\u2019\u2019-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478","volume":"11","author":"Lee","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.apradiso.2017.04.028_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0969-8051(00)00196-7","article-title":"Development of an in vitro model for assessing the in vivo stability of lanthanide chelates","volume":"28","author":"Li","year":"2001","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.apradiso.2017.04.028_bib20","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.addr.2008.04.006","article-title":"Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides","volume":"60","author":"Liu","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.apradiso.2017.04.028_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.nucmedbio.2005.01.003","article-title":"177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo","volume":"32","author":"Michel","year":"2005","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.apradiso.2017.04.028_bib22","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/jlcr.3204","article-title":"The effect of chelator type on in vitro receptor binding and stability in 177Lu-labeled cetuximab and panitumumab","volume":"57","author":"Novy","year":"2014","journal-title":"J. Label. Comp. Radiopharm."},{"key":"10.1016\/j.apradiso.2017.04.028_bib23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1515\/ract-2013-2190","article-title":"Investigation on the influence of metal ion impurities on the complexation behavior of generator produced 90Y with different bifunctional chelators","volume":"102","author":"Pandey","year":"2014","journal-title":"Radiochim. Act."},{"key":"10.1016\/j.apradiso.2017.04.028_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10967-015-4281-4","article-title":"A systematic evaluation of the potential of PCTA-NCS ligand as a bifunctional chelating agent for design of 177Lu radiopharmaceuticals","volume":"307","author":"Pandey","year":"2016","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"10.1016\/j.apradiso.2017.04.028_bib25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1874471008666150312160440","article-title":"Chemistry and bifunctional chelating agents for binding 177Lu","volume":"8","author":"Parus","year":"2015","journal-title":"Curr. Radiopharm."},{"key":"10.1016\/j.apradiso.2017.04.028_bib26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.apradiso.2017.04.028_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph5010001","article-title":"Pre-clinical assessment of 177Lu-labeled Trastuzumab targeting HER2 for treatment and management of cancer patients with disseminated intraperitoneal disease","volume":"5","author":"Ray","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apradiso.2017.04.028_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/cbr.1996.11.43","article-title":"Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy","volume":"11","author":"Srivastava","year":"1996","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.apradiso.2017.04.028_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10967-014-3240-9","article-title":"Aspects of yield and specific activity of (n,\u03b3) produced 177Lu used in targeted radionuclide therapy","volume":"302","author":"Vimalnath","year":"2014","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"10.1016\/j.apradiso.2017.04.028_bib30","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s10967-014-3590-3","article-title":"Lutetium-177 complexation of DOTA and DTPA in the presence of competing metals","volume":"303","author":"Watanabe","year":"2015","journal-title":"J. Radioanal. Nucl. Chem."}],"container-title":["Applied Radiation and Isotopes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804316305760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804316305760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T16:24:50Z","timestamp":1658939090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969804316305760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":30,"alternative-id":["S0969804316305760"],"URL":"https:\/\/doi.org\/10.1016\/j.apradiso.2017.04.028","relation":{},"ISSN":["0969-8043"],"issn-type":[{"value":"0969-8043","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic study on the utility of CHX-A\u2019\u2019-DTPA-NCS and NOTA-NCS as bifunctional chelators for 177Lu radiopharmaceuticals","name":"articletitle","label":"Article Title"},{"value":"Applied Radiation and Isotopes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apradiso.2017.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}